Search results
Added:
1 year ago
ACC 2025 - In this succinct video, Dr Dipti Itchhaporia (Hoag Heart and Vascular Institute & University of California, CA, US) outlines the key late-breaking trials from the conference that are expected to have an impact on clinical practice.Trials covered in detail include:FRESH-UPAPI-CATALIGN-ARPROTECT-TAVIRecorded on-site at ACC in Chicago, 2025.Support: This is an independent interview…
View more
Added:
1 year ago
Keep up to date with the top trials from AHA 24!CLEAR-SYNERGYSELECT-CABGSUMMITYELLOW IIIInternational Aortic Stenosis RegistryAMPLATZER IDEVALOR HCMWatch our full AHA 24 coverage in our Late-Breaking and Featured Science Collection.
View more
Added:
1 year ago
As part of e-SPACE Cardio-Renal-Metabolic 2024, Prof Intissar Haddiya, Dr Lars Lund, Prof Marco Metra, Prof Nikolaus Marx, Prof Peter Rossing and Prof Giuseppe Rosano discuss guideline directed therapy for CRM disease.
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
An artificial intelligence (AI)-augmented clinical programme may significantly improve the detection of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that is frequently underdiagnosed, according to the results of a new nonrandomized clinical trial.¹ The study evaluated an AI model, ATTRACTnet, in a real-world setting to identify patients missed by usual care.The ATTRACTnet model was…
View more
Added:
9 months ago
Originally delivered live, this roundtable programme brings together Prof James Burton (University of Leicester, Leicester, UK), Dr Clara Bonanad (University Clinical Hospital of Valencia, Valencia, ES), Dr Aaron Wong (Princess of Wales Hospital, Bridgend, Wales, UK) and Dr Csaba Kovesdy (University of Tennessee, Knoxville, US) to explore practical, evidence-based approaches to managing…
View more
Added:
1 month ago
Source:
CFR Journal Radcliffe Cardiology
A prespecified, secondary analysis of the MAPLE-HCM trial has shown that aficamten monotherapy provides superior and rapid benefits across multiple domains of disease burden compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM).¹ Aficamten is a next-in-class cardiac myosin inhibitor (CMI) designed to reduce myocardial hypercontractility by decreasing…
View more
Undiagnosed Sleep Apnoea Linked to Adverse Myocardial Remodelling in Hypertrophic Cardiomyopathy
Added:
7 months ago
Source:
Radcliffe Cardiology
News
Added:
2 years ago
ACC.24 — Dr Andrew P DeFilipis (Vanderbilt University Medical Center, US) joins us onsite at ACC to discuss the findings from a subgroup analysis of the MINT Trial (NCT02981407).MINT is a randomised parallel assignment trial which aims to compare liberal and restrictive blood cell transfusion strategies in patients who have had an acute myocardial infarction (AMI) and are anaemic. Findings were…
View more
ESC Congress 2025
Start date:
Aug 29, 2025
End date:
Sep 01, 2025
Event
Comparison of Haemodynamic Responses to Landiolol Versus Esmolol
Added:
10 months ago
Original Research